Literature DB >> 17382263

Tumour biology and histopathology of neuroendocrine tumours.

Günter Klöppel1.   

Abstract

The tumours of the disseminated/diffuse neuroendocrine cell system are a group of neoplasms sharing uniformly appearing cells which differ from each other in their biology, prognosis and genetics. In the lung they are called carcinoid and small/large-cell neuroendocrine carcinomas. In the gastroenteropancreatic compartment they are classified as well-differentiated neuroendocrine tumours or carcinomas and poorly differentiated neuroendocrine carcinomas. Depending on their localization these neoplasms reveal distinct phenotypes with respect to pathology, immunohistochemistry, and hormonal syndromes. Their clinical behaviour--ranging from benign and low-grade to high-grade malignancy--can be predicted on the basis of clinicopathological criteria. Currently extensive work is being performed to unravel the genetic background.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382263     DOI: 10.1016/j.beem.2007.01.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  39 in total

Review 1.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

2.  Imaging of phospholipids in formalin fixed rat brain sections by matrix assisted laser desorption/ionization mass spectrometry.

Authors:  Claire L Carter; Cameron W McLeod; Josephine Bunch
Journal:  J Am Soc Mass Spectrom       Date:  2011-09-01       Impact factor: 3.109

3.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

4.  Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT.

Authors:  Satomi Kawamoto; Pamela T Johnson; Chanjuan Shi; Aatur D Singhi; Ralph H Hruban; Christopher L Wolfgang; Barish H Edil; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

5.  177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

Authors:  Daniel Hubble; Grace Kong; Michael Michael; Val Johnson; Shakher Ramdave; Rodney John Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-06       Impact factor: 9.236

Review 6.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 7.  Cutaneous metastases as an initial manifestation of visceral well-differentiated neuroendocrine tumor: a report of four cases and a review of literature.

Authors:  Jaroslaw Jedrych; Klaus Busam; David S Klimstra; Melissa Pulitzer
Journal:  J Cutan Pathol       Date:  2013-12-03       Impact factor: 1.587

8.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.

Authors:  Balasubramanian Venkitaraman; Sellam Karunanithi; Arvind Kumar; G C Khilnani; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

9.  Invasive neuroendocrine tumor of the kidney: a case report.

Authors:  Ephrem O Olweny; Michael H Hsieh; Jill C Buckley; Jack W McAninch
Journal:  Rare Tumors       Date:  2009-12-28

Review 10.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.